Sanofi SA vs Xpeng Inc - ADR — how do they compare? Sanofi SA trades at $44.05 (market cap $104.83B), while Xpeng Inc - ADR trades at $13.35 (market cap $12.96B). The key difference: Sanofi SA is far larger — about 8.1× Xpeng Inc - ADR's market cap, and Sanofi SA pays a 5.5% dividend while Xpeng Inc - ADR pays none. Which is the better fit depends on your goals.
| SNY | XPEV | |
|---|---|---|
Market Cap | $104.83B | $12.96B |
Sector | Health | Consumer Cyclical |
52-Week High | $52.34 | $28.07 |
52-Week Low | $41.33 | $12.09 |
Enterprise Value | $121.32B | $15.07B |
Dividend Yield | 5.5% | — |
Trailing returns across standard periods
Latest headlines on both assets
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →Founded in 2015, XPeng is a leading Chinese smart electric vehicle, or EV, company that designs, develops, manufactures and markets EVs in China. Its products primarily target the growing base of technology-savvy middle-class consumers in the midrange to high-end segment in China's passenger vehicle market. The company sold over 98,000 EVs in 2021, accounting for about 3% of China's passenger new energy vehicle market. It is also a leader in autonomous driving technology.
Read more on XPEV →